Elicio Therapeutics, Inc.
ELTX
$2.18
-$0.17-7.23%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -5.90% | 2.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.63% | 19.90% | |||
| Operating Income | 1.63% | -19.90% | |||
| Income Before Tax | 30.50% | -53.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 30.50% | -53.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 30.50% | -53.19% | |||
| EBIT | 1.63% | -19.90% | |||
| EBITDA | 1.54% | -20.05% | |||
| EPS Basic | 34.23% | -30.44% | |||
| Normalized Basic EPS | 34.21% | -30.41% | |||
| EPS Diluted | 34.23% | -30.44% | |||
| Normalized Diluted EPS | 34.21% | -30.41% | |||
| Average Basic Shares Outstanding | 5.67% | 17.44% | |||
| Average Diluted Shares Outstanding | 5.67% | 17.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||